Safety of mifepristone in medical abortion in hyperthyroidism pregnant mice

Objective: To study the safety of mifepristone on thyroid hormone level by using hyperthyroidism pregnant model in mouse to simulate the process of medical abortion and observe the changes of thyroid hormone during abortion. Methods: A total of 60 female Institute of Cancer Research (ICR) mice aged...

Full description

Bibliographic Details
Published in:	Reproductive and Developmental Medicine
Main Authors:	Yun-Hui Tang, Xiao-Ying Yao
Format:	Article
Language:	English
Published:	Wolters Kluwer Health/LWW 2019-01-01
Subjects:	Hyperthyroidism; Medical Abortion; Mifepristone; Pregnant Mice
Online Access:	http://www.repdevmed.org/article.asp?issn=2096-2924;year=2019;volume=3;issue=1;spage=30;epage=35;aulast=Tang

Similar Items

Concurrent Use of Mifepristone and Misoprostol for Early Medical Abortion
by: Yiu-Tai Li, et al.
Published: (2006-12-01)

Use of Mifepristone and Sublingual Misoprostol for Early Medical Abortion
by: Mau Lin, et al.
Published: (2006-12-01)

Effectiveness and Safety of Medical Abortion with Mifepristone and Sublingual Misoprostol up to 63 Days of Gestation
by: Prakasit Saengbanyang, et al.
Published: (2024-09-01)

Mifepristone and Misoprostol Induced Abortion with A Large Myomatous Uterus
by: Yiu-Tai Li, et al.
Published: (2005-06-01)

A randomized comparison of three early medical abortion regimes: Mifepristone and misoprostol, misoprostol alone and methotrexate and misoprostol
by: Renuka Brijwal, et al.
Published: (2025-07-01)

Simultaneous use of mifepristone and misoprostol for early pregnancy termination
by: Yiu-Tai Li, et al.
Published: (2011-03-01)

Comparative study of sublingual versus vaginal misoprostol following mifepristone in early first trimester medical termination of pregnancy - a prospective study
by: B. L Pathak, et al.
Published: (2019-01-01)

Monitoring Medical Abortion Using Mifepristone/Misoprostol Combination with Ultrasonogram and Serum Human Chorionic Gonadotropin
by: Szu-Yuan Chou, et al.
Published: (2006-03-01)

High-Dose Misoprostol as An Alternative Therapy After Failed Medical Abortion
by: Yiu-Tai Li, et al.
Published: (2008-12-01)

Spatial Disparities in Mifepristone Use for Early Miscarriage and Induced Abortion Among Obstetrician–Gynecologists Practicing in Massachusetts
by: Emily Newton-Hoe, et al.
Published: (2024-04-01)

Pharmacist Dispensing of Mifepristone: Evaluation of Knowledge and Support Before and After a Continuing Education Course
by: Natalie Morris, et al.
Published: (2025-09-01)

Efficacy of Mifepristone/Misoprostol Combination for Medical Abortion Determined by Detection of Retained Products in a Community Hospital in Taipei, Taiwan
by: Szu-Yuan Chou, et al.
Published: (2004-06-01)

A prospective study on the effectiveness of a combination regime (Mifepristone and Misoprostol) in comparison with Misoprostol for missed abortion
by: Nidhi Gupta, et al.
Published: (2023-10-01)

Availability of medical abortion medicines in eight countries: a descriptive analysis of key findings and opportunities
by: Amy Grossman, et al.
Published: (2023-04-01)

A COMPARATIVE STUDY BETWEEN MIFEPRISTONE VS. PLACEBO AS AN UTERINE SENSITIZER FOR SECOND TRIMESTER ABORTIONS
by: Meetali Parashar, et al.
Published: (2019-12-01)

The Origins and Proliferation of Unfounded Comparisons Regarding the Safety of Mifepristone
by: Cameron Louttit
Published: (2025-05-01)

A descriptive summary of the WHO availability assessments of medical abortion medicines in eight African countries
by: Amy Grossman, et al.
Published: (2024-12-01)

Comparison of mifepristone plus misoprostol with misoprostol alone for first trimester medical abortion: A systematic review and meta-analysis
by: Tariku Shimels, et al.
Published: (2023-03-01)

Direct Effects of Mifepristone on Mice Embryogenesis: An In Vitro Evaluation by Single-Embryo RNA Sequencing Analysis
by: Yu-Ting Su, et al.
Published: (2023-03-01)

Medicamentous abortion with mifepristone and misoprostol in Serbia and Montenegro
by: Stojnić Jelena, et al.
Published: (2006-01-01)

Effectiveness and acceptability of home use of misoprostol for medical abortion up to 10 weeks of pregnancy
by: Volodymyr Podolskyi, et al.
Published: (2023-05-01)

Mifepristone Directly Disrupts Mouse Embryonic Development in Terms of Cellular Proliferation and Maturation In Vitro
by: Yu-Ting Su, et al.
Published: (2021-11-01)

Short‐term efficacy and safety of early medical abortion in Japan: A multicenter prospective study
by: Yutaka Osuga, et al.
Published: (2023-01-01)

To Study the Efficacy of Intraamniotic Prostaglandin F2 Alpha versus Mifepristone and Misoprostol Combination for Mid-trimester Medical Termination of Pregnancy
by: NM Anupam Kapur, et al.
Published: (2024-08-01)

Landscape assessment of the availability of medical abortion medicines in India
by: Priya Karna, et al.
Published: (2024-06-01)

ALTERNATIVE APPROACHES TO MEDICAL ABORTION
by: K. Telbiyska, et al.
Published: (2024-03-01)

Partial Hydatidiform Mole in a Medical Abortion with the Mifepristone/Misoprostol Combination
by: Pui-Ki Chow, et al.
Published: (2004-12-01)

Self-managed medication abortion outcomes: results from a prospective pilot study
by: Heidi Moseson, et al.
Published: (2020-10-01)

Acceptability of misoprostol-only medication abortion dispensed by mail-order or retail pharmacy: a qualitative study based on in-depth interviews in the United States
by: Dana M. Johnson, et al.
Published: (2025-12-01)

Differences in pain, bleeding, and satisfaction during medical abortion at very early gestations
by: Frida Gyllenberg, et al.
Published: (2025-09-01)

Comparison of Two Different Intervals of Misoprostol Administration in Second Trimester Abortions
by: Anjali Gupta, et al.
Published: (2023-06-01)

Outpatient medical management of later second trimester abortion (18–23.6 weeks) with procedural evacuation backup: A large case series
by: Sruthi Chandrasekaran, et al.
Published: (2024-01-01)

Determination of Mifepristone (RU-486) and Its Metabolites in Maternal Blood Sample after Pharmacological Abortion
by: Paweł Szpot, et al.
Published: (2022-11-01)

Women’s experiences and acceptability of medical termination of pregnancy: Results of an introductory study in Thailand
by: Kittipong Saejeng, et al.
Published: (2019-01-01)

The Association Between Self-Managed versus Clinician-Managed Abortion and Self-Reported Abortion Complications: A Cross-Sectional Analysis in India
by: Goemans S, et al.
Published: (2023-09-01)

Efficacy of a four-drug combined regimen compared to uterine curettage in the treatment of incomplete medical abortion: a prospective observational study
by: Yanlin Feng, et al.
Published: (2025-04-01)

Comparison of mifepristone combination with misoprostol and misoprostol alone in the management of intrauterine death
by: Damyanti Sharma, et al.
Published: (2011-09-01)

Cellular Effects of Naringin in Prevention of Genotoxicity Caused by Mifepristone on Human Blood Lymphocytes
by: Mohammad Shokrzadeh, et al.
Published: (2018-06-01)

Management of early pregnancy loss by reproductive endocrinologists: does access to mifepristone matter?
by: Zachary S. Anderson, M.D., et al.
Published: (2024-09-01)

Factors related to successful medication management with mifepristone and misoprostol in missed miscarriage: a retrospective case-control study
by: Huiyuan Wang, et al.
Published: (2025-05-01)